Levodopa

New Parkinson's Treatment Shows Promise in Animals

... controlled using the medication levodopa, When combined with another drug, levodopa is converted into dopamine in the brain. But as the disease progresses, the benefits from levodopa can diminish. Patients with Parkinson's who are no longer responding wel...

Parkinson's Treatment Drugs Even Out Over Long Term

... Levels of disability, quality of life similar on levodopa or pramipexole, study finds WEDNESDAY, March 11 (HealthDay News) -- Two drugs -- levodopa and pramipexole -- used to treat early stage Parki...ne in the brain that causes Parkinson's symptoms. levodopa is an amino acid that the body metabolizes into do...

Family History of Melanoma Doubles Parkinson's Risk

...found that Parkinson's patients taking levodopa, a common treatment for the condition, were more susceptible to melanoma, Gao said. "They thought that levodopa increased the risk of melanoma," he explained. But later reports found that people with melanoma were at high risk of developing Parkinson's diseas...

Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Sinemet(R) Tablets

...nnounced today, that it has launched Carbidopa and levodopa tablets on behalf of Sun Pharmaceutical Industries...A) for generic Sinemet(R) tablets. Carbidopa and levodopa tablets are used in the treatment of Parkinson's d... syndrome. These generic versions of Carbidopa and levodopa 10 mg / 100 mg, 25 mg / 100 mg, and 25 mg / 250 mg...

New Hope for Parkinson's Patients

... In the second study, a patch delivery system for levodopa also appeared to ease motor problems in Parkinson'...nts. The study compared healthy volunteers on a levodopa patch against those taking carbidopa orally every ...onstant therapeutic delivery of medication. "If levodopa can be administered in a way to bypass the gastroi...

Drug May Cut Tremors Associated With Parkinson's

... popular Parkinson's drug, found those using istradefylline experienced 24 percent less "off" time, defined as when the physical symptoms appear after levodopa wears off. A group of those studied who took a placebo showed a 10 percent decrease in "off" time. "These results suggest that istradefylline is ef...

Eye Cell Implants Improve Parkinson's Symptoms

... eye cells naturally begin to produce levodopa. The researchers believe the levodopa is then turned into dopamine, a neurotransmitter lacking in people with Par...atients selected for the study were chosen based on their responsiveness to levodopa and the severity of their symptoms when they were off their medication. Us...

'Proud Hands' Book Released to Benefit the American Parkinson Disease Association

...oms of Parkinson's disease both as initial therapy alone and to be added to levodopa later in the disease. The effectiveness of AZILECT was shown in patients wi...AZILECT alone are headache, joint pain and indigestion; and when taken with levodopa are uncontrolled movements (dyskinesias), accidental injury, nausea, weight...

Neupro(R) Filed with the FDA for the Treatment of Restless Legs Syndrome

...) is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy and as adjunctive therapy with levodopa in advanced-stage Parkinson's disease. About Restless Legs Syndrome: Restless legs syndrome (RLS) is a chronic neurological disorder that affects ...

Neupro(R) Filed with the FDA for the Treatment of Advanced-Stage Parkinson's Disease

...ine Transdermal System) as adjunctive therapy with levodopa in adult patients with advanced-stage Park...or the use of Neupro(R) as adjunctive therapy with levodopa in adult patients with advanced-stage Parkinson's ...nstrated that rotigotine, as adjunctive therapy to levodopa in patients with advanced-stage Parkinson's diseas...

Levodopa in Medical Technology

Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels

WELLESLEY HILLS, Mass., Aug. 25 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for the benefit of creditors, announced today that all pharmaceutical intellectual property will be sold at a sealed bid auction on October 10, 2008. SR...

Once Daily, Extended-Release Ropinirole Improves Parkinson's Symptoms in Patients not Optimally Controlled With Levodopa

'Off' Time Reduced By an Average of More Than Two Hours Per Day RESEARCH TRIANGLE PARK, N.C., April 02, 2007 /PRNewswire/ -- Adding the once daily, investigational medication REQUIP(R) (ropinirole HCl) XL 24-Hour(TM) Extended-Release Tablets to Parkinson's patients' existing levodopa (L-dopa) ther...

Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial

...es of a dopamine agonist and/or an anti-cholinergic drug. After a four-week levodopa dosage stabilization phase, study participants were randomized to one of th...r matching placebo tablets (222 patients), as adjunctive treatment to their levodopa therapy. The primary efficacy endpoint of the study was the increase in mea...

Kyowa Hakko Kirin Announces Development Policy for Anti-Parkinson's Disease Drug KW-6002 (Istradefylline)

...phenomenon*, a motor complication, while receiving levodopa therapy alone or in combination with other anti-Pa...ted primarily by dopamine replacement therapy with levodopa or dopamine agonists. Long term therapy with levodopa is associated with motor complications such as the...

Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics

...ment, levodopa, which could lessen debilitating side effects of the drug including dyskinesias, the uncontrollable movements that arise with long-term levodopa therapy (Verne Cowles, Ph.D., and S. Y. Eddie Hou, Ph.D., Depomed, Inc., Menlo Park, California); -- Validating a novel metabolomic diagnostic test ...

Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinson's Disease

...She will use the model to test drugs that can alleviate this 'non-motor' symptom, which might also allow for better delivery of existing drugs such as levodopa that must pass through the GI tract to enter the bloodstream. A complete list of researchers who were awarded grants under Target Validation 2007, i...

U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease

... Requip XL Improved Symptoms in Patients Not Optimally Controlled with levodopa and Reduced Patients' "Off" Time by Nearly Two Hours Per Day RESEARCH TRI...fficacy and safety trial showed that adding Requip XL to patients' existing levodopa (l-dopa) therapy reduced the amount of "off" time experienced by patients w...

Status of the E2007 (perampanel) Development Program

... 302 and 309) with perampanel as add-on therapy to levodopa in patients with late-stage disease. Additionally,...oms of Parkinson's disease return as the effect of levodopa wears off). Perampanel was generally well tolerate... different from that of dopaminergic drugs such as levodopa and dopamine agonists, in-depth review will be nec...

Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative

...ncluding strategies to alleviate complications of current treatments such as dyskinesias (the disruptive movements that are a side effect of long-term levodopa use).The Foundation is also eager to support development of treatments that address 'non-motor' aspects of PD, such as cognitive dysfunction, depressi...

BioMarin Announces FDA Approval for Kuvan

...e conditions should be carefully monitored when receiving Kuvan. Caution should be used with the administration of Kuvan to patients who are receiving levodopa and drugs that affect nitric oxide-mediated vasorelaxation or folate metabolism. The most serious adverse reactions reported during Kuvan administra...

Levodopa in Biological News

Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinson's

...She will use the model to test drugs that can alleviate this 'non-motor' symptom, which might also allow for better delivery of existing drugs such as levodopa that must pass through the GI tract to enter the bloodstream. The following is a complete list of researchers who were awarded grants under Target...

Cell-based therapy shows promise in patients with Parkinson's disease

...urvive in the brain. The implanted cells serve as a new potential source of levodopa to enhance dopamine production where it is most needed. The patients were selected based on disease stage, levodopa responsiveness, and severity of PD symptoms while off medication. An even ...

NIH announces phase III clinical trial of creatine for Parkinson's disease

...als. The study will enroll people who have been diagnosed with PD within the past five years and who have been treated for two years or less with levodopa or other drugs that increase the levels of dopamine in the brain. Many of the symptoms of PD result from the loss of dopamine, a neurotransmitter tha...

Levodopa in Biological Technology

Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity

...f Parkinson's disease (PD) both as initial therapy alone and to be added to levodopa later in the disease. IMPORTANT SAFETY INFORMATION ABOUT AZILECT ...ZILECT alone are headache, joint pain, and indigestion; and when taken with levodopa are uncontrolled movements (dyskinesias), accidental injury, nausea, weight...

New Report Provides Expert Analysis of Recent Advances and Setbacks in Parkinson's Disease Drug Development

... neurturin, neublastin, GAD/glutamic acid decarboxylase), alpha-synuclein; -- Dopamine agonists, monoamine oxidase inhibitors; -- levodopa formulations, COMT inhibitors; and -- Adenosine A2A receptor antagonists, cholinesterase inhibitors, AMPA, 5-HT, anticonvulsants, antihyper...